Synapse - David Kelsen

Results (13)

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Extracellular vesicle and particle biomarkers define multiple human cancers

Journal Article

Hoshino, A.; Kim, H. S.; Bojmar, L.; Gyan, K. E.; Cioffi, M.; Hernandez, J.; Zambirinis, C. P.; Rodrigues, G.; Molina, H.; Heissel, S.; more...
Cell (2020)

Fulltext@MSK | Save

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

Journal Article

Lowery, M. A.; Kelsen, D. P.; Capanu, M.; Smith, S. C.; Lee, J. W.; Stadler, Z. K.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; more...
European Journal of Cancer (2018)

Fulltext@MSK | Save

Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)

Meeting Abstract

Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

Journal Article

Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
Cancer (2017)

Fulltext@MSK | Save

Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC)

Meeting Abstract

Lowery, M. A.; Kelsen, D. P.; Smith, S. C.; Moore, M.; Kindler, H. L.; Golan, T.; Segal, A.; Hollywood, E.; Maynard, H.; Capanu, M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)

Meeting Abstract

O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC)

Meeting Abstract

O'Reilly, E. M.; Lowery, M. A.; Yu, K. H.; Capanu, M.; Stadler, Z. K.; Epstein, A. S.; Golan, T.; Segal, A.; Segal, M.; Salo-Mullen, E. E.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)